Dr Oguchi said it was also simple to store the cells; he therefor plans to develop a tissue bank - as long as the funding is forthcoming, estimating that will take a decade to achieve, and give future scientists a range of genetic codes that can be matched to a patient to minimise the risk of
transplanted organs of tissue being rejected. Dr Ogushi said that people who have their wisdom teeth removed as youngsters could have them frozen and use them later in life for treatment.
Embryome Sciences develops new medical products using embryonic stem cell technology and is a subsidiary of BioTime Inc., reported on 21 August that the company has licensed a portfolio of patents and patent applications from Advanced Cell Technology Inc with respect to induced pluripotent stem cells and embryonic stem cell differentiation technology.
The company is applying the license for the commercialisation of products in human therapeutic and diagnostic product markets. The technology covers methods for the transformation of cells of the human body, such as skin cells, into an embryonic and pluripotent state.
Red Blood Cells Providing New Incentives for Advanced Cell Technology
Could red blood cells be mass-produced? Advanced Cell Technology (ACTC) is a Los Angeles, California-based company devoted to turning human embryonic stem cells into therapies. On 19 August, the journal Blood published a paper reporting the efficient production of red blood cells from human embryonic stem cells.
Lead author was Robert Lanza, chief scientific officer at ACT (his co-authors are from the University of Illinois, Chicago, and the Mayo Clinic in Rochester, Minnesota). Up to 100 billion cells had been generated from a single plate of stem cells. The cells produced had oxygen-carrying abilities and physiological responses comparable to those of the cells from blood banks used in transfusions.
Advanced Cell Technology has 3 major products in the FDA Clinical Trials Pipleline: one to do with retinal repair, another with myoblast repair, after a heart attack, and the other is a hepatic (liver) repair stem cell product; this latest development puts a very obvious fourth feather in their hat....
The paper "clearly shows that stem cells could serve as an unlimited source of blood for transfusion in the future," Lanza says. "The potential here could be enormous."
"This is a major advance because it shows for the first time that these cells can be expanded; they can create [red] blood cells and they can carry oxygen," says Anthony Atala, the director of the Wake Forest Institute for Regenerative Medicine in Winston-Salem, North Carolina. "Blood therapies and blood replacement agents are an area of large need."
While the company searches for a big deal to stabilize it financially, Lanza says, "We are still going paycheck to paycheck." That's a familiar feeling for veterans of the 14-year-old company, he notes. "It's probably the fifth or sixth time we've had the phones turned off. When you get in trouble, that's your first warning." Lanza appeared with Barbara Walters on her show on April 1 to discuss in great deal the future and prospects of the specific stem cell research he directs at Advanced Cell Technology.
Although ACTC has in the FDA Clinical Trials pipeline stem cell products in three key ares (retinal respair, hepatic repair, and myoblast [after-heart attack] repair, Advanced Cell Technology has been living precariously on signing smaller licensing deals.
On 21 August, the life-sciences research company Embryome Sciences, a subsidiary of BioTime, announced a licensing agreement with ACT. Embryome, based in Alameda, California, has licensed a portfolio of patents related to virus-free induced pluripotent stem cells and embryonic stem cell differentiation technology.
Moving ACT's red blood cell method to the clinic, there are also questions about the commercial prospects for a product that would have to compete with freely donated blood.
"It's certainly a very exciting result from a scientific perspective," says Cathy Prescott, the director of Biolatris, a biotechnology and health-care consulting company in Cambridge, UK.
Thanks to the Telegraph, the London newspaper; to Medical News today (UK), and Dr. Catherine Paddock, to Embryome Press release, and to Meredith Wadman's article in Naturenews.
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
